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Abstract
Aims/hypothesis Glitazones are powerful insulin sensitisers
prescribed for the treatment of type 2 diabetes. Their use is,
however, associated with fluid retention and an increased risk
of congestive heart failure. We previously demonstrated that
pioglitazone increases proximal sodium reabsorption in
healthy volunteers. This study examines the effects of
pioglitazone on renal sodium handling in individuals prone to
insulin resistance, i.e. those with diabetes and/or hypertension.
Methods In this double-blind randomised placebo-controlled
four-way crossover study, we examined the effects of
pioglitazone (45 mg daily during 6 weeks) or placebo on
renal, systemic and hormonal responses to changes in sodium
intake in 16 individuals, eight with type 2 diabetes and eight
with hypertension.
Results Pioglitazone was associated with a rapid increase in
body weight and an increase in diurnal proximal sodium
reabsorption, without any change in renal haemodynamics
or in the modulation of the renin–angiotensin aldosterone
system to changes in salt intake. A compensatory increase
in brain natriuretic peptide levels was observed. In spite of
sodium retention, pioglitazone dissociated the blood-
pressure response to salt and abolished salt sensitivity in
salt-sensitive individuals.
Conclusions/interpretation Pioglitazone increases diurnal
proximal sodium retention in diabetic and hypertensive
individuals. These effects cause fluid retention and may
contribute to the increased incidence of congestive heart
failure with glitazones.
Trial registration: ClinicalTrial.gov NCT01090752
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Introduction
Glitazones are efficient oral hypoglycaemic agents with
powerful insulin-sensitising properties that have sustained
effects on blood sugar control [1]. Awell known side effect is
fluid retention exacerbated by insulin use. Peripheral oedema
is seen in 5–15% of treated individuals. This side effect just
about doubles the risk of congestive heart failure, but does
not increase mortality [2]. There is no evidence that the
increased risk of heart failure is due to a negative inotropic
effect [3, 4], thus fluid retention remains the major contributor.
Based on these clinical observations, restriction of
glitazones to individuals without congestive heart failure
(CHF) New York Heart Association class III or IV has been
recommended. The European Union has extended the
recommendations to all individuals with New York Heart
Association class I–IV CHF.
We have previously shown that glitazones increase renal
sodium reabsorption in healthy volunteers [5]. Both direct
and indirect effects of glitazones on renal sodium reabsorption
have been proposed, through the direct activation of tubular
peroxisome proliferator-activated receptor (PPAR)-γ or indi-
rectly through the activation of compensatory mechanisms
secondary to the glitazone-induced vasodilation [6–8]. Ex-
perimental studies have shown that glitazones may increase
sodium transport in the proximal convoluted tubules, the
thick ascending limb and the collecting duct [9, 10].
The primary endpoint of this placebo-controlled, rando-
mised, crossover study was to explore the effects of
pioglitazone (45 mg once daily for 6 weeks) on the renal,
hormonal and blood pressure responses to changes in
sodium intake in a population prone to insulin resistance
(i.e. hypertensive and/or type 2 diabetic individuals).
Although many studies have been performed in animals,
this is the first study to examine in hypertensive and/or type
2 diabetic individuals the renal sodium response to
pioglitazone when exposed to a high- or a low-sodium diet.
Methods
Sixteen individuals were examined, eight with a diagnosis
of type 2 diabetes and eight with a diagnosis of systemic
hypertension. The participants were recruited by hospital
placards detailing the study. Participants received a sum as
compensation for travel and meal expenses. Exclusion
criteria were any cardiac or renal diseases, anaemia and
drugs such as aspirin, non-steroidal anti-inflammatory
drugs and hormonal replacement therapy.
A full medical history was obtained and a complete
physical examination was undertaken before inclusion. Type
2 diabetes was defined according to the American Diabetes
Association criteria (fasting plasma glucose ≥7.0 mmol/l or
casual plasma glucose ≥11.1 mmol/l in individuals without
diabetic treatment). Among the eight individuals with
diabetes, three were on a diet and five were treated with
metformin that was maintained at the same dose throughout
the study. Individuals receiving glitazone therapy or using
insulin were excluded. Hypertension was defined as an office
systolic blood pressure ≥140 mmHg and/or a diastolic blood
pressure ≥90 mmHg in individuals not using blood-pressure-
lowering therapy. Among the diabetic individuals, three were
taking either an angiotensin II receptor antagonist or an ACE
inhibitor. Among hypertensive individuals, one was taking an
ACE inhibitor. Blood-pressure-lowering therapy was discon-
tinued for at least 2 weeks and individuals were included in the
study if values did not exceed 160/100 mmHg. Premeno-
pausal women were excluded, as were individuals with
liver abnormalities or renal failure. The protocol was
approved by the local hospital ethical committee in
accordance with the principles of the Declaration of
Helsinki as revised in 2000, and written informed consent
was obtained from each individual.
Procedure
The study had a double-blind, randomised, placebo-
controlled, twofold crossover design as shown in Fig. 1. A
total of 64 ambulatory blood pressure measurement and
hormonal and renal function studies were planned. Each
individual was randomised to receive either pioglitazone
45 mg once daily or (during the placebo phase) either placebo
(if on diet alone before entering the study) or metformin (usual
dose if on therapy before entering the study) for 6 weeks, with
a 2 week wash-out period between the two treatment phases.
Randomisation of the sequences of placebo and active
treatment periods was performed by a doctor with no contact
with participants and clinicians. Placebo and active treatment
were prepared by a pharmacist, appeared indistinguishable
and were dispensed in identical bottles.
From weeks 1 to 4, individuals followed their usual diet.
During weeks 5 and 6 of each treatment phase (placebo or
pioglitazone), individuals received a low-sodium (LS) and a
high-sodium (HS) diet for 1 week. The sequence of the
diets was randomised, but each individual received the
same sequence while receiving placebo or pioglitazone.
The random allocation scheme was derived from a
computer-generated list, which assigned diets according to
a random sequence of numbers. Individuals were instructed
to adjust their diet to reach a sodium intake of approxi-
mately 40 mmol/24 h. The high-sodium diet was obtained
by adding 6 g of sodium chloride to the individual’s regular
diet. On day 7 of each dietary period, 24 h ambulatory
blood pressure was recorded, with measurements performed
at 20 min intervals from 08:00 to 22:00 hours, and at
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30 min from 22:00 to 08:00 hours (Diasys, Physicor,
Geneva, Switzerland). This device has been validated by
the British Hypertension Society and rated B/B [11].
Simultaneously, diurnal and nocturnal urine were collected
separately to measure sodium, potassium and endogenous
lithium excretions. Participants were instructed not to
smoke or to drink alcohol or any caffeine-containing
beverages during that day. On the following day, the
participants were investigated in the research unit, after an
overnight fast, to undergo clearance studies as reported
previously [12]. In brief, two intravenous catheters were
inserted into antecubital veins, one for the infusion of
sinistrin (an analogue of inulin) and para-aminohippurate
(PAH) and a second into the contralateral forearm for
drawing blood. After an oral water load of 5 ml/kg and a
90 min equilibration period, two 1 h sinistrin and PAH
clearances were obtained to measure glomerular filtration
rate and effective renal plasma flow (ERPF). Blood was also
drawn to measure serum electrolytes, including endogenous
lithium, as well as plasma renin activity (PRA), plasma
aldosterone, atrial natriuretic factors (ANP) and brain
natriuretic peptide (BNP). Blood sampling for hormonal
measurements was done supine after an hour of rest and
before the water load. Leg volume was measured at the end
of each phase and through a water immersion method.
Analytical method and calculation of renal variables
Insulin sensitivity indexes were assessed by HOMA-IR
[13]. Urinary and plasma sodium and potassium were
measured by flame photometry (IL-943, Instrumentation
Laboratory, Milan, Italy) and creatinine by the picric acid
method (Cobas-Mira, Roche, Basel, Switzerland). Serum
and urinary uric acid was measured by the enzymatic
method using an uricase–peroxidase chromogen sequence
(AUPAP50, bioMérieux, Lyon, France, on a Cobas-Mira,
Roche). Plasma and urinary sinistrin and PAH were
determined by photometry (Autoanalyzer II-Technicon,
Bran & Luebbe, Norderstedt, Germany). Lithium clearance
was used as a marker of renal proximal sodium clearance.
Endogenous trace lithium was measured by atomic absorp-
tion spectrophotometry as described previously [14].
Plasma renin activity [15, 16], plasma aldosterone [17]
and atrial natriuretic peptide [18] were determined as
described previously. BNP was measured by immunoassay
(Biosite Triage BNP test, Biosite, Morges, Switzerland).
Plasma insulin was determined by radioimmunoassay
(Insulin-RIA, Pharmacia, Dübendorf, Switzerland).
Urinary electrolyte excretion rate was calculated as Ux × V
(μmol/min) and clearance (ml/min) calculated using the
standard formula Cx ¼ Ux  V=Px where Ux and Px are the
urine and plasma concentrations of x and V is the urine flow
rate in ml/min.
Statistical analysis
Data are expressed as mean ± SEM. The statistical
difference between the four different treatment periods
(LS/placebo, HS/placebo, LS/pioglitazone, HS/pioglitazone)
was evaluated for each variable by a one-way analysis of
variance followed by the Fischer’s comparison test. A level
of p<0.05 was considered statistically significant. To
examine the specific effects of pioglitazone in the same
individual, the values obtained with placebo were
subtracted from the values obtained with pioglitazone.
The significance was examined by a one-sample t test for
a significant difference from 0, with the zero value
indicating no change; p<0.05 was considered statistically
significant.
Results
Baseline characteristics of the individuals and tolerability
profile
The baseline characteristics of individuals are shown in
Table 1. There were no significant differences between the
hypertensive and diabetic individuals. Among the hyper-
tensive individuals, three had impaired fasting glucose and
ABPM, U24
Renal function study
ABPM,U24
Renal function study
1 2 3 4 5 6 7Week
Pioglitazone 45 mg or placebo 
Diet 1
Diet 2
ABPM, U24
Renal function study
ABPM, U24
Renal function study
1 2 3 4 5 6 7Week
Diet 1
Diet 2
2 weeks
Placebo  or pioglitazone 45 mg 
Fig. 1 Detail of the 6 week
study period, repeated twice:
once with pioglitazone and once
with placebo, with a 2 week
wash-out period. The sequence
of diets was randomised, but
each sequence was the same for
a given individual. ABPM, am-
bulatory blood pressure mea-
surement; U24, 24 h urine
collection
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one had impaired fasting glucose and impaired glucose
tolerance. No individual dropped out from the study.
Tolerability to treatment was assessed at each visit by asking
questions. Reported side effects were headache during
infusion of PAH for two patients, and feeling of bloating
for seven individuals during the high-salt-diet periods.
As there were no significant differences between the
hypertensive and diabetic individuals, all further results are
shown and analysed for the pooled group of all 16 patients.
Metabolic variables
No metabolic variable changed significantly during the
study, although there was a clear trend towards a decrease
in plasma insulin levels, HOMA-IR and uric acid levels
during the pioglitazone phases (Table 2).
Weight and leg volume The average increase in weight with
pioglitazone was of 1.1±0.5 kg on a low-sodium diet (p =
Characteristic Diabetic (n=8) Hypertensive (n=8) All (n=16)
Age (years) 56.8±3.2 48.4±4.4 52.5±2.8
Sex (female/male) 4/4 4/4 8/8
Weight (kg) 77.0±6.5 81.4±5.4 79.2±4.1
BMI (kg/m2) 27.7±1.9 28.0±1.2 27.9±1.1
Mean SBP (mmHg) 138.9±3.5 150.5±4.8 144.7±3.2
Mean DBP (mmHg) 84.3±3.7 93.0±2.7 88.7±2.5
Haematocrit (%) 43.3±1.9 43.2±1.6 43.2±1.2
ALAT (U/l) 46.4±9.2 52.2±9.5 49.3±6.2
Serum creatinine (μmol/l) 78±5.6 70±3.3 74±3.3
OGTT
Glycaemia 0′ (mmol/l) 5.5±0.3
Glycaemia 120′ (mmol/l) 5.9±0.6
Table 1 Baseline characteristics
of individuals
ALAT, alanine transaminase;
DBP, diastolic BP; SBP, systolic
BP
Table 2 Metabolic, hormonal and renal measurements
Variable Placebo Pioglitazone ANOVA
LS HS LS HS p value
Blood
Glucose (mmol/l) 6.8±0.4 6.3±0.3 6.9±0.7 6.9±0.7 NS
Insulin (pmol/l) 208.4±45.8 168.1±23.6 125.7±12.5 127.1±14.6 NS
HOMA-IR 8.9±1.8 6.3±0.9 5.5±0.7 5.4±0.8 NS
ALAT (U/l) 35±5.4 32.8±5.5 33.9±3.6 32.1±5.0 NS
Uric acid (mmol/l) 378±21 343±14 346±23 323±21 NS
Protein (g/l) 72.8±0.9 69.3±0.7a 70.9±1.1 68.7±0.9a 0.01
PRA (ng ml−1 h−1) 1.03±0.3 0.37±0.13a 0.86±0.2 0.20±0.09a 0.006
Aldosterone (pg/ml) 119.6±18.7 70.6±6.8a 113.0±15.6 66.5±6.0a 0.006
ANP (pg/ml) 25.8±5.1 41.8±6.2 26.6±5 40.3±6.2 0.085
BNP (pg/ml) 6.7±9.5 12.8±4.9 11.0±4.8 17.3±5.3b 0.4
Renal function studies
UNa (mmol/24 h) 59±16 166±21a 65±17 163±20a <0.001
Na clearance (ml/min) 0.41±0.10 1.05±0.10a 0.35±0.07 1.18±0.13a <0.001
GFR (ml min−1 [1.73 m2]−1) 68.0±4.4 68.8±5.0 62.4±5.0 71.7±6.7 NS
ERPF (ml min−1 [1.73 m2]−1) 397±34 381±35 354±41 316±36 NS
FF (%) 0.19±0.02 0.20±0.02 0.26±0.09 0.36±0.14 NS
a HS diet vs LS diet on same drug
b Pioglitazone vs placebo on same salt diet
ALAT, alanine transaminase; ERPF, effective renal plasma flow; UNa, 24 h urinary Na excretion
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0.04 vs 0) and of 1.3±0.6 kg (p=0.05) on a high-sodium
diet. The increase in weight induced by pioglitazone was
not significantly amplified by a high-sodium diet (p=0.6).
In comparison with the low-sodium diet, the high-sodium
diet induced a weight gain of 1.57±0.31 kg (p=0.0002)
during the placebo phase and of 1.84±0.56 kg during the
pioglitazone phase (p=0.005); the differences were not
significant between pioglitazone and placebo. When the
weight with the placebo low-sodium-diet phase was
considered as a baseline, the increase in weight was
comparable during the high-sodium placebo phase and the
low-sodium pioglitazone phase and was highest during the
high-sodium pioglitazone phase (Fig. 2a). Changes in
protein levels were inversely correlated with changes in
body weight (y=0.992–0.184x, p=0.01) (Fig. 2b). Changes
in leg volume were slightly but not significantly bigger
when switching from a low-sodium to a high-sodium diet
during the pioglitazone phase (control phase vs pioglita-
zone phase, 0.3±0.1% vs 0.5±0.4%).
Hormonal measurements The high-sodium diet was
associated with a decrease in PRA and aldosterone
levels and an increase in ANP and BNP levels (Table 2).
The diet-induced changes, however, reached significant
levels only with PRA, aldosterone, ANP and BNP in
diabetic individuals. In particular, changes in BNP levels
were more pronounced in diabetic individuals: the
mean ± SEM for LS/placebo, HS/placebo, LS/pioglitazone
and HS/pioglitazone phases were, respectively, 5.8±2.3,
12.1±3.0, 6.2±1.7, 15.7±2.9 pg/ml (p=0.03). When exam-
ining the pioglitazone-induced hormonal changes, the only
significant effect was the changes in BNP level during a
high-sodium diet. Figure 3 depicts the individual
pioglitazone-induced change in BNP levels; average changes
were significantly higher with the high-sodium diet. The
pioglitazone-induced changes in BNP levels were not
significantly different during the high- and low-sodium-diet
phases.
Renal function studies Urinary sodium excretion (mmol/
day) was higher on a high- vs a low-sodium diet during
placebo and pioglitazone phases (Table 2). Lithium clear-
ances (ml/min) increased also with the high-sodium diet
during the placebo phase but not during the pioglitazone
phase. Overall lithium clearances were significantly lower
during the pioglitazone phase than during the placebo phase
(p=0.03). The average diurnal and nocturnal lithium
clearance rates during different phases are shown in
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Fig. 3 Pioglitazone-induced individual and mean (±SEM) changes in
BNP levels from values obtained with placebo on the low-sodium or
high-sodium diet: †p=0.1, ‡p=0.006 for changes from low-sodium
and high-sodium diets, respectively
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Fig. 4. The increase in lithium clearance in response to the
increase in sodium intake was observed exclusively during
the day. This effect was abolished with pioglitazone.
Changes in GFR, ERBF and filtration fraction (FF) were
not significant during both diets and during the placebo and
pioglitazone phases (Table 2).
Ambulatory blood pressure measurements Ambulatory
blood pressure measurements are shown in Table 3. The
high-sodium diet increased blood pressure slightly but not
significantly. Pioglitazone did not have a significant effect on
blood pressure control. The weight gain induced by a high-
sodium diet was not correlated with the blood pressure
response to salt. Salt sensitivity was defined as an increase
inmean 24 h ambulatory blood pressure on a high-sodium diet
of >5 mmHg. Of all individuals examined, three diabetic
individuals and one hypertensive individuals fulfilled the
criteria for salt sensitivity. On the high-sodium diet, 24 h mean
blood pressure increased by a range of 6–17 mmHg in these
salt-sensitive individuals. In these individuals, pioglitazone
treatment abolished the blood pressure response to salt
(Fig. 5). The pioglitazone induced changes in BP response
to salt were significantly different in salt-sensitive and salt-
resistant individuals (p=0.04). In other words, the salt-
sensitive individuals became salt resistant with pioglitazone
treatment.
Discussion
Glitazones are powerful insulin sensitisers which are
associated with sodium retention and an increased risk of
congestive heart failure. This study was designed to
examine the renal, hormonal and blood pressure response
in diabetic and/or hypertensive individuals when exposed to
a 1 week low- or high-sodium diet after 6 weeks of
pioglitazone, 45 mg, in comparison with placebo.
This study demonstrates that pioglitazone treatment is
associated with a rapid increase in body weight, due to
sodium retention. Pioglitazone increases diurnal proximal
sodium reabsorption without changing the renal haemody-
namics or altering the modulation of the renin–angiotensin
aldosterone system to changes in salt intake. These results
suggest an effect of pioglitazone, either direct or indirect,
on renal sodium handling. Compensatory mechanisms were
observed, as demonstrated by the increase in natriuretic
BNP levels with pioglitazone. These compensatory mech-
anisms may have prevented a drastic increase in body
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Fig. 4 Average lithium clearances (mean ± SEM) during different
phases: diurnal, nocturnal and 24 h. *p<0.05 vs high-sodium/placebo
Variable Placebo Pioglitazone
LS HS LS HS
24 h 128±5/80±2 134±5/81±3 129±5/79±2 133±4/80±2
Diurnal 131±5/82±2 138±6/84±3 135±5/83±2 138±4/83±2
Nocturnal 115±5/72±3 118±4/72±2 114±5/70±2 116±4/71±2
Table 3 Blood pressure ambu-
latory measurements in different
treatment groups
Data shown are mean systolic
BP ± SEM/mean diastolic
BP ± SEM
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Fig. 5 Individual and mean (±SEM) changes in 24 h mean
ambulatory blood pressure measurements from a low-sodium diet to
a high-sodium diet in salt-sensitive and salt-resistant individuals
during the placebo and pioglitazone phases. †p=0.02 for difference
in salt-sensitive individuals and NS for salt-resistant individuals
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weight when exposed to a high-sodium diet. This study also
demonstrates that, in spite of sodium retention, pioglitazone
dissociates the blood pressure response to salt and abolishes
salt sensitivity in salt-sensitive individuals.
Glitazones can influence body composition in different
ways. Long-term studies show an increase in body fat in
favour of a subcutaneous distribution [19–22]. In contrast,
shorter-term studies demonstrate that the rapid increase in
body weight is chiefly due to fluid retention. One 12 week
study demonstrated that 75% of the increase in body weight
was due to water [23]. In our study, 6 weeks of pioglitazone
treatment was associated with changes in plasma protein
levels that mirrored the changes in body weight, suggesting
that fluid retention accounted for most of the increase in
body weight during the pioglitazone phase.
The mechanisms of fluid retention due to glitazone
therapy have been examined in experimental studies. Short-
term animal studies also show that there is a rapid increase
in body weight during the first week of treatment, clearly
due to an increase in water content [6, 7] and an increase in
the epithelial sodium channel (ENaC) activity. These effects
were inhibited by amiloride, an ENaC inhibitor, and
abolished in mice with specific deletion of the collecting
duct PPAR-γ suggesting an important role of glitazone-
induced sodium retention through ENaC. These studies
were welcomed with enthusiasm, as a specific treatment
targeting ENaC is available in clinical practice (amiloride,
spironolactone). However, clinical experience was not as
successful as hoped with spironolactone, even though one
clinical study showed superiority of spironolactone com-
pared with furosemide for glitazone-induced fluid retention
[8]. Recently, another experimental study cast some doubt
on the effects of glitazones on ENaC. In this study, the
collecting duct gene inactivation of α-ENaC did not
prevent the rosiglitazone-induced fluid retention and neither
rosiglitazone nor pioglitazone increased the activity of basal
or insulin-stimulated ENaC in native collecting duct cells
[24]. The contradictory results illustrate the complexity of
glitazone-induced sodium reabsorption. Although rapid
activation of renal sodium transporters may occur, com-
pensatory or escape mechanisms may take place with time
[25], either through the downregulation of sodium trans-
porters or through the increase in natriuretic peptides. The
inability to activate the compensatory mechanisms or
concurrent treatment with insulin may alter these compen-
satory mechanisms and enhance fluid retention.
Changes in body weight during the 1 week sodium
challenges were exclusively due to fluid shifts. Endogenous
lithium clearances show that the kidney was unable to
modulate proximal sodium reabsorption during the piogli-
tazone phase. However, compensatory mechanisms attenu-
ated this effect with the consequent increase in body weight
of only 270 g during the pioglitazone phase from the
placebo phase when switching from a low-sodium to a
high-sodium diet.
We have previously shown in an experimental study that,
in spite of significant weight gain and water retention,
glitazones dissociate the blood pressure response to salt and
decrease the blood pressure response to angiotensin II [26].
Human studies show that treatment with rosiglitazone or
pioglitazone is either neutral or associated with a mild
decrease in blood pressure [27]. This study confirms for the
first time that a sodium load during 1 week does not
significantly change the blood pressure response in spite of
increased sodium retention at the proximal level. These
findings suggest that with pioglitazone, there are enough
compensatory mechanisms—through vasodilation or in-
creased release of natriuretic peptides—to compensate for
the fluid retention and keep blood pressure low. Interest-
ingly, a subset of salt-sensitive individuals became salt
resistant during the pioglitazone phase. The relevance of
these findings now needs to be confirmed in a larger study.
In contrast to our previous study in healthy volunteers,
there was no increase in renin levels with pioglitazone [5].
This difference may be due to the fact that pioglitazone
induced less vasodilation in our participants, because of
endothelial dysfunction, than in healthy volunteers.
Some limitations of the study need to be addressed. The
sample size may seem small but the crossover design of the
study increased the statistical power. The goal was to
explore the mechanisms of sodium retention with glita-
zones. Each of 16 individuals was examined four times
with complete renal function studies, hormonal and 24 h
blood measurements, and each served as their own control.
This would not be possible in a population study. If a case–
control study had been performed, a much higher number
of individuals would have been needed to show a difference
between cases and control because of the inter-individual
variability of renal and hormonal measurements. Adherence
to sodium intake was not monitored, but the significant
hormonal and renal changes gave an indirect validation to
good observance.
In conclusion, this study shows that pioglitazone
increases proximal tubular sodium retention after 6 weeks,
independent from a change in renal haemodynamics, and is
counteracted by the release of BNP. Whether the glitazone-
induced increase in congestive heart failure is linked to
sustained proximal sodium reabsorption and decreased
compensatory release of natriuretic factors needs to be
examined in population studies.
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